Journey Medical Corp
DERM8.940USD
-0.250-2.72%
交易中 （美東）報價延遲15分鐘
209.84M總市值
虧損本益比TTM
關於 Journey Medical Corp 公司
Journey Medical Corporation 是一家商業階段製藥公司。該公司專注於開發和商業化用於治療皮膚病的藥品。其產品組合包括七種品牌和兩種授權仿製處方藥，用於治療皮膚病，這些藥物均在美國銷售。其銷售的產品已獲得美國食品藥品管理局 (FDA) 的批准，包括 Qbrexza、Accutane、Amzeeq、Zilxi、Exelderm 乳膏和溶液、Targadox 和 Luxamend。該公司銷售兩種授權仿製產品，包括硝酸硫康唑乳膏和溶液以及鹽酸多西環素速釋片 50mg。Qbrexza 是一種用於治療原發性腋窩多汗症的藥用布巾。Accutane 是一種口服異維甲酸藥物，用於治療嚴重的頑固性結節性痤瘡。Targadox 是一種口服強力黴素藥物，用於嚴重痤瘡的輔助治療。
Journey Medical Corp簡介
公司代碼DERM
公司名稱Journey Medical Corp
上市日期Nov 12, 2021
CEOMr. Claude Maraoui
員工數量41
證券類型Ordinary Share
年結日Nov 12
公司地址9237 E Via De Ventura Blvd., Suite 105
城市SCOTTSDALE
上市交易所NASDAQ Capital Market Consolidated
國家United States of America
郵編85258
電話14804346670
網址https://journeymedicalcorp.com/
公司代碼DERM
上市日期Nov 12, 2021
CEOMr. Claude Maraoui
Journey Medical Corp公司高管
名稱
名稱/職務
職務
持股
持股變動
Mr. Claude Maraoui
Mr. Claude Maraoui
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.06M
+150.79%
Dr. Lindsay A. Rosenwald, M.D.
Dr. Lindsay A. Rosenwald, M.D.
Executive Chairman of the Board
Executive Chairman of the Board
377.89K
+15.25%
Mr. Ramsey Alloush
Mr. Ramsey Alloush
Chief Operating Officer, General Counsel
Chief Operating Officer, General Counsel
316.68K
+17.37%
Mr. Joseph Benesch, CPA
Mr. Joseph Benesch, CPA
Chief Financial Officer, Corporate Controller
Chief Financial Officer, Corporate Controller
100.78K
+40.22%
Mr. Neil Herskowitz
Mr. Neil Herskowitz
Independent Director
Independent Director
98.89K
+25.35%
Ms. Miranda Jayne Toledano
Ms. Miranda Jayne Toledano
Independent Director
Independent Director
98.89K
+25.35%
Mr. Michael C. Pearce
Mr. Michael C. Pearce
Independent Director
Independent Director
57.17K
+53.80%
Ms. Jaclyn Jaffe
Ms. Jaclyn Jaffe
Investor Relations
Investor Relations
--
--
Mr. Justin Smith
Mr. Justin Smith
Independent Director
Independent Director
--
--
名稱
名稱/職務
職務
持股
持股變動
Mr. Claude Maraoui
Mr. Claude Maraoui
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.06M
+150.79%
Dr. Lindsay A. Rosenwald, M.D.
Dr. Lindsay A. Rosenwald, M.D.
Executive Chairman of the Board
Executive Chairman of the Board
377.89K
+15.25%
Mr. Ramsey Alloush
Mr. Ramsey Alloush
Chief Operating Officer, General Counsel
Chief Operating Officer, General Counsel
316.68K
+17.37%
Mr. Joseph Benesch, CPA
Mr. Joseph Benesch, CPA
Chief Financial Officer, Corporate Controller
Chief Financial Officer, Corporate Controller
100.78K
+40.22%
Mr. Neil Herskowitz
Mr. Neil Herskowitz
Independent Director
Independent Director
98.89K
+25.35%
Ms. Miranda Jayne Toledano
Ms. Miranda Jayne Toledano
Independent Director
Independent Director
98.89K
+25.35%
收入明細
單位: USD更新時間: 10月6日 週一
單位: USD更新時間: 10月6日 週一
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
業務USD
名稱
營收
佔比
Qbrexa
6.95M
46.30%
Accutane
3.40M
22.62%
Emrosi
2.79M
18.62%
Amzeeq
879.00K
5.86%
Other branded revenue
735.00K
4.90%
Zilxi
256.00K
1.71%
地區USD
名稱
營收
佔比
United States
15.01M
100.00%
業務
地區
業務USD
名稱
營收
佔比
Qbrexa
6.95M
46.30%
Accutane
3.40M
22.62%
Emrosi
2.79M
18.62%
Amzeeq
879.00K
5.86%
Other branded revenue
735.00K
4.90%
Zilxi
256.00K
1.71%
股東統計
更新時間: 10月14日 週二
更新時間: 10月14日 週二
持股股東
股東類型
持股股東
持股股東
佔比
Fortress Biotech Inc
16.55%
Maraoui (Claude)
10.15%
Tang Capital Management, LLC
9.13%
Wasatch Global Investors Inc
5.67%
The Vanguard Group, Inc.
2.78%
其他
55.72%
持股股東
持股股東
佔比
Fortress Biotech Inc
16.55%
Maraoui (Claude)
10.15%
Tang Capital Management, LLC
9.13%
Wasatch Global Investors Inc
5.67%
The Vanguard Group, Inc.
2.78%
其他
55.72%
股東類型
持股股東
佔比
Corporation
16.55%
Individual Investor
16.12%
Hedge Fund
10.86%
Investment Advisor
10.71%
Investment Advisor/Hedge Fund
10.28%
Insurance Company
0.89%
Research Firm
0.32%
Private Equity
0.16%
Pension Fund
0.07%
其他
34.04%
機構持股
更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
113
6.77M
33.31%
+424.31K
2025Q2
93
10.34M
59.77%
+53.87K
2025Q1
89
9.75M
61.79%
-68.70K
2024Q4
83
8.33M
55.97%
-821.12K
2024Q3
84
6.72M
45.26%
-1.40M
2024Q2
79
7.11M
49.43%
-621.27K
2024Q1
70
6.34M
49.52%
-781.26K
2023Q4
68
5.80M
46.63%
-1.25M
2023Q3
54
6.63M
53.88%
+189.20K
2023Q2
50
5.90M
48.59%
-532.43K
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Fortress Biotech Inc
3.36M
16.55%
--
--
Apr 14, 2025
Maraoui (Claude)
2.06M
10.15%
+1.24M
+150.79%
Aug 25, 2025
Tang Capital Management, LLC
1.85M
9.13%
--
--
Jun 30, 2025
Wasatch Global Investors Inc
1.15M
5.67%
+221.46K
+23.80%
Jun 30, 2025
The Vanguard Group, Inc.
564.99K
2.78%
+192.73K
+51.77%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
480.30K
2.36%
+437.14K
+1012.83%
Jun 30, 2025
Rosenwald (Lindsay A)
377.89K
1.86%
+50.00K
+15.25%
Aug 05, 2025
Essex Investment Management Company, LLC
228.20K
1.12%
+216.74K
+1890.08%
Jun 30, 2025
Alloush (Ramsey)
316.68K
1.56%
+46.86K
+17.37%
Jun 17, 2025
Geode Capital Management, L.L.C.
262.35K
1.29%
+148.61K
+130.66%
Jun 30, 2025
查看更多
持股ETF
更新時間: 11月6日 週四
更新時間: 11月6日 週四
機構名稱
佔比
iShares Micro-Cap ETF
0.02%
iShares Russell 2000 Growth ETF
0.01%
Global X Russell 2000 ETF
0%
ProShares Hedge Replication ETF
0%
iShares Russell 2000 ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
0%
Dimensional US Core Equity 1 ETF
0%
ProShares UltraPro Russell2000
0%
Royce Quant Small-Cap Quality Value ETF
0%
Proshares Ultra Russell 2000
0%
iShares Micro-Cap ETF
佔比0.02%
iShares Russell 2000 Growth ETF
佔比0.01%
Global X Russell 2000 ETF
佔比0%
ProShares Hedge Replication ETF
佔比0%
iShares Russell 2000 ETF
佔比0%
DFA Dimensional US Sustainability Core 1 ETF
佔比0%
Dimensional US Core Equity 1 ETF
佔比0%
ProShares UltraPro Russell2000
佔比0%
Royce Quant Small-Cap Quality Value ETF
佔比0%
Proshares Ultra Russell 2000
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
